Smartest Doc
New epidemiological data provide additional safety evidence for lantus Full Text
Sanofi, 06/13/2012
Sanofi announced new results of a large–scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University of North Carolina in the United States, providing further evidence that there was no increased risk of cancer in people with diabetes treated with Lantus (insulin glargine [rDNA origin] injection), compared to those treated with other insulins. These data were presented at the American Diabetes Association 72nd Scientific Sessions.